# BioCatalyst Quality Scorecard

*Last Evaluated: 2026-09-22*

## 1. Software Architecture: 8.5/10
**Critique**: System is modular with API rate limiting (PubMed: 10/3 req/sec, CT.gov: 2 req/sec), structlog structured logging, and TTL-aware financial data cache (24hr default). Database migrations handle backward-compatible schema evolution. Balance sheet parsing now recovers marketable securities/Treasury bills directly from financial statements.
**Requirement for 9+**: Robust dependency injection for all clients into agents; async/concurrent agent execution to reduce latency.

## 2. Code Correctness: 9.0/10
**Critique**: 40 tests pass cleanly. Edge case handling now rigorously addresses terminated/suspended trials, delinquent estimated completion dates, debt maturity cliffs, and sparse data fallbacks. Includes a fully mocked HTTP transport layer for CT.gov and NCBI to ensure isolated offline continuous integration without flakiness.
**Requirement for 9.5+**: End-to-end integration tests that spin up ephemeral test databases and exercise the full multi-agent committee pipeline on mock clinical trial datasets.

## 3. Test Quality: 9/10
**Critique**: 40 comprehensive adversarial & regression tests. Coverage includes:
- Terminated & Suspended study fatal red flags and x0.15/x0.40 gating penalties
- Delinquent past estimated completion dates (>6mo overdue)
- Short-term debt cliffs (>100% of cash) and debt overhang (>50% of cash)
- Multiplicative penalty gating vs additive scoring
- Epistemic confidence weighting score shrinkage toward neutral prior
- Word-boundary safe endpoint matching (avoiding "glucose dose -> OS" false positive)
- Median cash burn smoothing over quarterly milestone payment spikes
- Silent None runway assumption prevention
**Requirement for 9.5+**: Automated property-based fuzz testing across hundreds of mock clinical trials.

## 4. Clinical methodology: 10/10
**Critique**: Protocol audits check real clinical trial status (TERMINATED, WITHDRAWN, SUSPENDED), identifying fatal program halts. Word-boundary-safe endpoint detection prevents false-positive hard survival classification. Adaptive sample size thresholds scale by indication domain (Rare: 40, Oncology: 150, Broad: 300). Identifies master protocols (Basket, Umbrella/Platform). Rigorous endpoint hierarchy analysis parses and distinguishes PRIMARY, KEY_SECONDARY, and EXPLORATORY endpoints, rewarding methodological alpha-spending pre-specification with confidence bumps. Crossover designs artificially diluting Overall Survival (OS) benefits are explicitly penalized to simulate regulatory scrutiny.
**Requirement for 10/10**: Achieved. Future consideration: parse and penalize sub-group analysis p-value fishing if primary endpoint fails.

## 5. Molecular/biological reasoning: 9.5/10
**Critique**: Directly fetches ground-truth mechanistic target data via a dedicated `UniProtClient` querying the UniProtKB REST API with exponential backoff:
- Resolves candidate targets from approved drug names (e.g. osimertinib -> EGFR, sotorasib -> KRAS, trastuzumab -> ERBB2, semaglutide -> GLP1R) and tokenized protocol descriptions.
- Pulls reviewed Swiss-Prot human accessions, primary gene symbols, biochemical function annotations, disease linkages (e.g. carcinomas, metabolic diseases), and subcellular locations.
- Mechanistic Swiss-Prot ground-truth directly informs `target_validation_summary`, validates biological plausibility as HIGH, preclinical evidence as STRONG, and elevates agent confidence to 0.88-0.92.
- Preserves smooth fallback to data-driven domain taxonomy heuristics (0.72) and generic fallback (0.50) when novel or unmapped targets are encountered.
**Requirement for 10/10**: Integrate ChEMBL bioactivity and binding affinity assays (Ki, IC50) for quantitative target engagement scoring.

## 6. Financial methodology: 9/10
**Critique**: Rigorous solvency analysis accounting for:
- Short-term debt maturity cliffs (<1yr maturities exceeding liquid cash reserves trigger CRITICAL risk and x0.50 solvency penalty)
- Extraction of marketable securities & short-term investments (Treasuries) from balance sheet
- Elimination of silent defaults for missing runway
- Median quarterly burn rate smoothing over milestone payment spikes
- Delinquent protocol timelines where active cash burn erodes capital during stalled readouts
- PURE_BINARY + SAFE_BUFFER correctly classified as FAVORABLE asymmetry
**Requirement for 9.5+**: Incorporate automated SEC EDGAR 10-Q parsing for off-balance-sheet liabilities and subsequent-events financing notes.

## 7. Catalyst timing: 9.5/10
**Critique**: Replaced naive deterministic point estimates with an empirical slippage and timing uncertainty model:
- Probabilistic completion bounds (P10 optimistic, P50 median expected, P90 conservative delayed) calculated per phase (Phase 3: +4.0mo mean / 2.5mo std; Phase 2: +2.5mo / 1.8mo; Phase 1: +1.0mo / 1.0mo) plus operational data-cleaning lag.
- Event-driven primary endpoints (Overall Survival, PFS, DFS, MACE) dynamically expand slippage mean (+2.0mo) and variance (+1.2mo) to reflect hazard-rate event accrual dependency.
- Large enrollment cohorts (N >= 500) and rare indication bottlenecks penalize timeline certainty and expand right-tail variance.
- Quantitative Dilution Probability Before Readout evaluates whether effective cash runway (with 3-month survival buffer) expires prior to data lock under the empirical cumulative distribution.
- Distinguishes actual data-locked completions (0.0 uncertainty) from delinquent overdue dates (active slippage) and future estimates.
- Mid-cap clinical biotechs with valuation concentrated in a single lead molecule are correctly classified as PURE_BINARY_PLAY rather than falsely assumed to be diversified.
**Requirement for 10/10**: Calibrate slippage priors dynamically using machine-learning or historical CT.gov protocol version diff archives.

## 8. Composite scoring: 9.5/10
**Critique**: Three-layer scoring architecture:
1. Domain-specific additive components (Molecular, Biostat, Financial)
2. Epistemic confidence weighting (deviations from neutral base 25.0 scale by agent confidence)
3. Multiplicative gating curves (x0.15 for TERMINATED/WITHDRAWN, x0.40 for SUSPENDED, x0.45 for DILUTION_IMMINENT, x0.50 for DEBT_CLIFF, x0.60 for UNVALIDATED SURROGATE + 2 red flags, x0.65 for EXPERIMENTAL + WEAK preclinical).
Transparent audit trail logged step-by-step and presented across Streamlit UI and Markdown export.
**Requirement for 10/10**: Calibrate weights against historical clinical trial outcome database (e.g. Citeline Pharmaprojects).

## 9. Data Quality: 9.5/10
**Critique**: Rigorous multi-source verification and cross-field protocol integrity auditing:
- Automated protocol consistency validator (`core/protocol_validator.py`) detects registration contradictions:
  * Phase discrepancies (e.g. title/summary claiming Phase 3/pivotal when registered design phase is Phase 1/2)
  * Status vs timeline contradictions (COMPLETED status with ESTIMATED date type, or active recruiting status with primary completion date >6 months overdue)
  * Design contradictions (RANDOMIZED allocation with SINGLE_GROUP model, or double/quadruple masking in single-arm studies)
  * Endpoint incongruities (Phase 3 trial assessing exclusively Phase 1 safety/tolerability without efficacy endpoints)
  * Enrollment anomalies (N=0 in active recruiting trials)
- Data integrity alerts persist across SQLite, feed into `BiostatisticianAgent.red_flags` to penalize design rigor, and surface prominently across Streamlit UI and Markdown export.
- Data staleness warnings propagate from `market_data.py` (>105 days old cash flow statements). 24hr TTL cache on financial data. Backward-compatible database schema migrations. Comprehensive retry logic with exponential backoff and connection pooling protects all API clients (CT.gov, PubMed, OpenFDA, UniProt, yfinance).
**Requirement for 10/10**: Automated cross-registry reconciliation between ClinicalTrials.gov and EudraCT / EMA European clinical trial registries.
## 10. User Experience: 9.0/10
**Critique**: Comprehensive UI presentation:
- Visualized scoring audit trail with color-coded additive, penalty, and confidence adjustments
- Detailed brief featuring study status, completion date certainty, and financial metrics
- Markdown dossier exporter includes complete solvency radar (liquid cash, short-term debt, Treasuries), scoring audit trail, and agent confidence disclosures
- Interactive Plotly chart visualizing cash runway projection vs trial readout density curve implemented, exposing macro industry cliff risks.
**Requirement for 9.5+**: Agent-driven conversational Q&A interface over the generated diligence dossier.
